Form 4: Terns Pharmaceuticals Director David Fellows Granted 45,000 Stock Options

Terns Pharmaceuticals, Inc. Director David A. Fellows was granted 45,000 stock options with an exercise price of $4.10, as reported in a recent SEC Form 4 filing.

Summary

• David A. Fellows, a Director of Terns Pharmaceuticals, Inc. (TERN), acquired 45,000 stock options on June 11, 2025.
• Each stock option has an exercise price of $4.10.
• The options will vest in full on the earlier of the first anniversary of the grant date (June 11, 2026) or immediately prior to the Annual Meeting following the grant date.
• The stock options are set to expire on June 10, 2035.
• Following this transaction, Mr. Fellows directly beneficially owns 45,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of continued commitment and aligns management incentives with shareholder interests, reflecting a standard compensation practice.

Positives

• The grant of 45,000 stock options to Director David A. Fellows aligns his interests with shareholders, incentivizing long-term company performance and value creation.
• The options have a 10-year expiration date (June 10, 2035), providing a substantial window for potential value realization.

Future Outlook

This filing details an equity grant to a director, which is a standard compensation practice intended to align management incentives with future company performance. It does not provide broader forward-looking statements regarding company operations or financial projections.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, used to attract and retain talent and align executive interests with long-term shareholder value creation, particularly in companies like Terns Pharmaceuticals that are typically in development stages.

Comparison to Industry Standards

• The grant of 45,000 stock options to a director is a typical form of equity compensation in the biotech sector, comparable to practices at similar-stage biopharmaceutical companies.
• The exercise price of $4.10 reflects the stock price at the time of grant, a standard approach for incentive options.

Related Party Transactions

• The grant of stock options to David A. Fellows, a Director of Terns Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align management's long-term interests with those of shareholders, potentially leading to increased focus on share price appreciation.
• Employees: While not directly impacting general employees, such grants are part of a broader compensation philosophy that can influence overall company culture and retention strategies for key personnel.

Next Steps

• The granted stock options will vest on the earlier of June 11, 2026, or immediately prior to the Annual Meeting following the grant date, at which point David A. Fellows will be able to exercise them.

Key Dates

Keywords

Terns Pharmaceuticals, TERN, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, David A. Fellows